Cargando…
Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
Osteosarcoma affects about 2.8% of dogs with cancer, with a one-year survival rate of approximately 45%. The purpose of this study was to characterize mutation and expression profiles of osteosarcoma and its association with outcome in dogs. The number of somatic variants identified across 26 sample...
Autores principales: | Das, Sunetra, Idate, Rupa, Regan, Daniel P., Fowles, Jared S., Lana, Susan E., Thamm, Douglas H., Gustafson, Daniel L., Duval, Dawn L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505454/ https://www.ncbi.nlm.nih.gov/pubmed/34635775 http://dx.doi.org/10.1038/s42003-021-02683-0 |
Ejemplares similares
-
Integrated analysis of canine soft tissue sarcomas identifies recurrent mutations in TP53, KMT genes and PDGFB fusions
por: Das, Sunetra, et al.
Publicado: (2023) -
Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma
por: Fowles, Jared S., et al.
Publicado: (2016) -
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
por: Regan, Daniel P., et al.
Publicado: (2022) -
TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021) -
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)